Vireo GrowthFRA:K95 -5.39%44 Current Ratio is 1.20 as of Mar. 2026, which is 33% below its 10-year median of 1.80. GuruFocus rates FRA:K95 with a GF Score™ of 44/100 and a GF Value™ of €7.54 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 998 Drug Manufacturers companies, Vireo Growth ranks worse than 75.75% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Vireo Growth's current ratio for the quarter that ended in Mar. 2026 was 1.20.
Vireo Growth has a current ratio of 1.20. It generally indicates good short-term financial strength.
The historical rank and industry rank for Vireo Growth's Current Ratio or its related term are showing as below:
FRA:K95'
s Current Ratio Range Over the Past 10 Years
Min: 0.04 Med: 1.8 Max: 57.25
Current: 1.2
During the past 13 years, Vireo Growth's highest Current Ratio was 57.25. The lowest was 0.04. And the median was 1.80.
FRA:K95's Current Ratio is ranked worse than 75.75% of 998
companies
in the Drug Manufacturers industry
Industry Median: 1.995
vs FRA:K95: 1.20
Vireo Growth (FRA:K95) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Vireo Growth Current Ratio Related Terms
Vireo Growth Current Ratio Historical Data
* Premium members only.
The historical data trend for Vireo Growth's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vireo Growth's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vireo Growth Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vireo Growth's Current Ratio distribution charts can be found below:
* The bar in red indicates where Vireo Growth's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vireo Growth (FRA:K95) has a Current Ratio of 1.20 as of Mar. 2026. This is 33% below median its historical median of 1.80. Over the past decade, Vireo Growth's Current Ratio has ranged from 0.04 to 57.25. According to the industry distribution chart, Vireo Growth ranks #756 out of 998 companies in the Drug Manufacturers industry, placing it in the top 75.8%.
Is Vireo Growth's Current Ratio too high?
Vireo Growth's current Current Ratio of 1.20 is 33% below median its 10-year median of 1.80. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 57.25. The Drug Manufacturers industry median Current Ratio is 2.00. Vireo Growth's value of 1.20 is 39.8% below this industry median. Based on the distribution chart, Vireo Growth ranks #756 out of 998 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Vireo Growth has a GF Score™ of 44/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vireo Growth's Current Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vireo Growth ranks #756 out of 998 companies for Current Ratio. This places Vireo Growth in the lower half of its industry. The industry median Current Ratio is 2.00. Vireo Growth's value of 1.20 is 39.8% below this benchmark. Historically, Vireo Growth's own Current Ratio has ranged from 0.04 to 57.25 over the past decade. While the company's 10-year median is 1.80 vs. the industry median of 2.00, Vireo Growth has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 998 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vireo Growth's current Current Ratio of 1.20 is 39.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vireo Growth's current Current Ratio is 1.20, which is 33% below median its own 10-year median of 1.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vireo Growth stock overvalued right now?
Based on GuruFocus' analysis, Vireo Growth (FRA:K95) is currently considered Modestly Overvalued. The stock's GF Value™ is €7.54, compared to a current price of €8.42 — trading 11.7% above its estimated fair value. The current Current Ratio is 1.20, which is 33% below median its 10-year median of 1.80 and 39.8% below the Drug Manufacturers industry median of 2.00. Vireo Growth's overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Vireo Growth (FRA:K95), the current Current Ratio is 1.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vireo Growth (FRA:K95) Overvalued in 2026?
Based on GuruFocus' analysis, Vireo Growth stock appears to be overvalued.
The current stock price of €8.42 is trading 11.7% above its estimated GF Value™ of €7.54.
GuruFocus considers Vireo Growth to be Modestly Overvalued.
Key valuation signals for FRA:K95:
Current Ratio: 1.20 (33% below median its 10-year median of 1.80)
GF Value™: €7.54 vs. price of €8.42 (11.7% above fair value)
Industry Position: 39.8% below the Drug Manufacturers median (#756 of 998)
No single metric tells the full story. See the FRA:K95 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vireo Growth Incis a cannabis company whose mission is to provide safe access, quality products and value to its customers while supporting its local communities through active participation and restorative justice programs. The Company is evolving with the industry and is in the midst of a transformation to being significantly more customer-centric across its operations, which include cultivation, manufacturing, wholesale and retail business lines. The company operates in one single segment.
44GF Score
Get the complete analysis for FRA:K95
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:K95 has been successfully added to your 
